## Diagnostic Criteria for HCC in Cirrhotic Patients **Key Point:** AASLD (American Association for the Study of Liver Diseases) guidelines recommend non-invasive diagnosis of HCC in cirrhotic patients using imaging criteria without need for biopsy when nodules meet specific size and enhancement patterns. ### Imaging Diagnosis Algorithm ```mermaid flowchart TD A[Nodule detected on surveillance]:::outcome --> B{Nodule size?}:::decision B -->|< 10 mm| C[Follow-up ultrasound every 3-4 months]:::action B -->|10-20 mm| D{AFP and imaging findings?}:::decision B -->|> 20 mm| E[One imaging modality showing arterial enhancement + washout]:::action D -->|AFP > 400 AND one imaging study shows typical pattern| F[HCC diagnosed]:::outcome D -->|AFP < 400 OR atypical imaging| G[Biopsy or follow-up imaging]:::action E --> F ``` ### AASLD Diagnostic Criteria (Cirrhotic Patients) | Nodule Size | Diagnostic Requirement | |---|---| | < 10 mm | Surveillance only | | 10–20 mm | **One imaging modality** showing arterial enhancement + washout **AND** AFP > 400 ng/mL, **OR** two imaging modalities with typical pattern | | > 20 mm | **One imaging modality** (CT or MRI) showing arterial phase enhancement + portal venous/delayed phase washout is sufficient | **High-Yield:** In this case, the nodule is **3 cm (> 20 mm)** with elevated AFP (320 ng/mL). A **single contrast-enhanced CT or MRI** showing arterial enhancement and washout is diagnostic and does **not** require biopsy confirmation. ### Why CT/MRI Over Other Modalities - **Sensitivity & Specificity:** CT and MRI have 80–90% sensitivity and > 95% specificity for HCC diagnosis in cirrhotic livers when using arterial phase enhancement + washout criteria. - **Standardized Criteria:** These modalities are the gold standard in AASLD, EASL (European Association for the Study of the Liver), and KLCSG (Korean Liver Cancer Study Group) guidelines. - **Spatial Resolution:** Superior to ultrasound for detecting enhancement patterns in cirrhotic livers with background heterogeneity. **Clinical Pearl:** Arterial phase enhancement (APHE) reflects the hypervascular nature of HCC due to neoangiogenesis and increased hepatic arterial supply. Washout in portal venous or delayed phase reflects rapid clearance of contrast, distinguishing HCC from benign regenerative nodules. **Warning:** Do not confuse with ~~biopsy~~ — biopsy is reserved for nodules 10–20 mm with discordant imaging or when imaging is inconclusive. Biopsy is NOT the first-line investigation for a 3 cm nodule with typical imaging features. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.